Skip to main content
. 2023 Feb 24;21:72. doi: 10.1186/s12916-023-02738-5

Fig. 1.

Fig. 1

Study flow chart. ALK, anaplastic lymphoma kinase. NSCLC, non-small cell lung cancer. PD, progressive disease. ECOG, Eastern Cooperative Oncology Group. PS, performance status. FAS, full analysis set. PPS, per-protocol set. TRAEs, treatment-related adverse events. RES, response evaluable set. IRC, independent review committee. PK, pharmacokinetics